Most patients starting brolucizumab switch from prior anti-VEGF therapy

Posted on

Approximately 94% of patients initiating treatment with brolucizumab for wet AMD switched from a different anti-VEGF treatment, according to data presented at AAO 2020 Virtual.

Using patients with wet AMD included in the IRIS Registry, researchers analyzed patient characteristics and early outcomes from 10,594 eyes (9547 patients) that had received ≥1 brolucizumab injection.

The majority of patients (88%) were treated unilaterally with brolucizumab and the baseline visual acuity was ≥20/40 in 47.4% of eyes that included visual acuity data.

Of the 93.7% of patients who had previously been treated with a different anti-VEGF agent, 70.8% were switching from aflibercept, 14.6% from ranibizumab, and 14.6% from bevacizumab.

Zarbin MA, et al. Profiles and Early Outcomes of Patients Who Initiated Brolucizumab for Neovascular (Wet) AMD in the IRIS® Registry. Presented at: AAO 2020 Virtual Meeting

Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021